At a press conference last September 22, Trump and Kennedy made claims that there was an increased risk of autism and ADHD in children whose mothers took acetaminophen, the active ingredient in Tylenol, during pregnancy. Even Kennedy admitted in October that the evidence was “not sufficient to say” that Tylenol causes autism or ADHD. The combined effect is that Tylenol’s overall Consideration score for all U.S. adults is only slightly down, from 48.2% on Sept. 22 to 46% on Jan. 19. From 43.5% on September 22, the score climbed to 60.3% by October 14, a gain of nearly 17 points in under a month. The increase stands out as one of the larger short-term movements for the brand in recent years.